Dental and bunion surgeries were the targets of the clinical trials and the drug was tolerated well. BD
The Food and Drug Administration has given Xanodyne Pharmaceuticals the go-ahead to market its Zipsor prescription pain reliever in a liquid-filled capsule, the company said Wednesday.
Zipsor, a non-steroidal anti-inflammatory drug, was shown to be effective at a low dose (25 mg), in trials involving post-surgical pain treatment after bunionectomies.
Xanodyne wins FDA approval for Zipsor capsules - Business Courier of Cincinnati:
Technorati Tags: FDA,pain relief,Xanodyne,healthcare,Zipsor,post surgery pain,dental surgery,bunions
0 comments :
Post a Comment